- Trial Phase
- Phase 3 (registrational)
- Time to Market
- Estimated 2028-2029 if Embolden topline data (2H 2027) supports BLA submission and FDA approval
- Why 5/10
- The next major hard catalyst is the mid-2026 updated Phase 1/2 data with 12+ month follow-up for all 10 participants (not a binary registrational readout). The definitive binary event — topline results from the Embolden registrational trial — is anticipated in 2H 2027, roughly 12-18 months out. NGN-401 is the company's sole lead asset, but the next truly binary catalyst is too distant to warrant a higher impact score.
NGN-401 is approaching its next data update (mid-2026), and positive details could sustain momentum, but the stock's defining event is the Embolden topline readout in 2H 2027. Watch for any safety signals (HLH risk was confined to the abandoned high-dose cohort) and for the magnitude of milestone gains vs. Taysha's TSHA-102. Cash runway through Q1 2028 provides a wide berth, reducing near-term dilution risk.
Price Chart
Executive Summary
NGN-401 is Neurogene's lead and essentially only pipeline asset — a one-time gene therapy for Rett syndrome, a severe rare neurological disorder affecting ~1 in 10,000 females. The drug has generated strong efficacy signals in Phase 1/2 (100% of 10 participants showed functional improvements, 35 developmental milestones gained across the group) and has secured FDA Breakthrough Therapy, RMAT, Fast Track, and Orphan Drug designations. The Embolden registrational trial completed dosing in June 2026, with topline data expected 2H 2027. The main rival is Taysha Gene Therapies' TSHA-102, while Acadia's Daybue (trofinetide) is the only currently approved Rett therapy but is a daily symptomatic treatment, not a one-time gene therapy. Cash of $243.2M (Q1 2026) provides runway into Q1 2028. Analyst consensus is Strong Buy with a mean price target of $80 (~150% upside).
How It Works
NGN-401 is a one-time gene therapy delivered directly into the brain's fluid spaces. It uses a harmless virus shell (AAV9) to deliver a working copy of the MECP2 gene — the gene that is mutated in Rett syndrome. Neurogene's proprietary EXACT technology regulates how much of the protein is produced, aiming to avoid toxicity from over-expression while restoring normal function. Rett syndrome is a severe neurodevelopmental disorder that mostly affects girls, causing loss of speech, hand function, and motor skills after an apparently normal early development.
Trial Status
The Embolden registrational trial has completed dosing of 25 participants (exceeding the 20-patient target) as of June 8, 2026. This single-arm, open-label, baseline-controlled study evaluates NGN-401 in females with Rett syndrome. Topline data is expected in 2H 2027. A Phase 1/2 trial remains ongoing with updated 12+ month follow-up data expected mid-2026. Dosing in the high-dose (3E15 vg) cohort was paused after a serious adverse event, but the lower 1E15 vg dose continues with a clean safety profile.
The Two-Sided Case
Upcoming Catalysts
- Mid-2026: Updated Phase 1/2 data with 12+ months of follow-up for all 10 participants
- 2H 2027: Topline results from Embolden registrational trial (the primary binary event)
- Ongoing: Process performance qualification (PPQ) campaign for commercial manufacturing
- Post-Embolden: Planned BLA submission to FDA
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Neurogene Inc. 424B5 NGNE ·Originating report